Advertisement

Topics

Serono Japan Company Limited Company Profile

00:26 EDT 22nd September 2017 | BioPortfolio

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).

We currently focus on three core therapeutics areas:



Reproductive Health Multiple Sclerosis

Growth & Metabolism



We are also investing strongly in the future, as expressed by our New Therapeutic Areas.



Global reach

We operate in 45 countries and have sales in over 100 countries.

Location

Kokusai Sanno Building 9th Fl.
3-3-5 Akasaka, Minato-ku
Tokyo
107-0052
Japan

Contact

Phone: +81-3-5545-7200
Fax: +81-3-5545-7209


News Articles [848 Associated News Articles listed on BioPortfolio]

INC Research expands Japan office

INC Research Holdings, a global phase I to IV CRO, announced the expansion and relocation of its Tokyo, Japan, office in support of the company’s long-term growth strategy both in Japan and across t...

EMD Serono to Present Data Highlighting Investigational Cladribine Tablets at CMSC 2017

ROCKLAND, Mass., May 25, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced 14 presentations, including ...

Japan: NKorea fires possible missile, could land off Japan

Japan's prime minister says North Korea has fired what is believed to be a missile and it may have landed in the sea off Japan.

VINTAGE SHIMADZU KALNEW MICROSCOPE JAPAN

AU $99.90End Date: Saturday Jul-22-2017 13:23:52 ESTBuy It Now for only: AU $99.90Buy It Now | Add to watch list Biotech365 : VINTAGE SHIMADZU KALNEW MICROSCOPE JAPAN BioMarketplace You want to p...

MetLife Hong Kong Expands Coverage for People with Diabetes and Introduces Insurtech Solution

HONG KONG, CHINA -- (Marketwired) -- 09/19/17 -- MetLife Hong Kong* announced today that it has extended the scope of its "MetLife Health-is-Wealth Medical Plan" to include people living with diabete...

Eli Lilly Reports Japan Marketing Approval For Olumiant

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte Corp. (INCY) announced the Japan's Ministry of Health, Labor and Welfare granted marketing approval for Olumiant (baricitinib) 2-mg ...

Interphex Japan, In─Pharma Japan to be held from June 28 to 30 in Tokyo

Japan's largest pharma shows, Interphex Japan and In─Pharma Japan will be held from June 28 to 30, 2017 at the Tokyo Big Sight in Tokyo, Japan. These shows are expected to gather 1,860 exhibitors an...

Japan's MHLW approves Olumiant to treat rheumatoid arthritis

Eli Lilly and Company and Incyte announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant (baricitinib) 2-mg and 4-mg tablets for the treatment of rh...

PubMed Articles [568 Associated PubMed Articles listed on BioPortfolio]

Avelumab: First Global Approval.

Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Da...

Nationwide epidemiological survey of early chronic pancreatitis in Japan.

The world's first diagnostic criteria for early CP were proposed in 2009 in Japan. This study aimed to clarify the clinico-epidemiological features of early CP in Japan.

First progress report on the Japan Endoscopy Database (JED) project.

The Japan Endoscopy Database (JED) Project was initiated to develop the world's largest endoscopic database, capture the actual performance of endoscopic practice, and standardize the terminology and ...

Japan Prize/Special Award in Synthetic Organic Chemistry, Japan/CNRS Medals.

Current status of portal vein thrombosis in Japan: Results of a questionnaire survey by the Japan Society for Portal Hypertension.

To investigate the current status of portal vein thrombosis (PVT) in Japan, the Clinical Research Committee of the Japan Society of Portal Hypertension conducted a questionnaire survey.

Clinical Trials [391 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Ser...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

Companies [1874 Associated Companies listed on BioPortfolio]

Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Serono Japan Company Limited

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).We currently focus on three core therapeutics areas:Reproductive Health Multiple Sclerosis Growt...

Serono Inc.

Serono is a global biotechnology leader with over 4,750 employees and worldwide revenues of USD 2,586.4 million in the year 2005. We have eight biotechnology products on the market and currently more ...

Serono Laboratories Incorporated

We develop innovative products to fight debilitating diseases and improve the lives of our patients.We aspire to create an environment that enables our people to excel and innovate and to contribute t...

More Information about "Serono Japan Company Limited" on BioPortfolio

We have published hundreds of Serono Japan Company Limited news stories on BioPortfolio along with dozens of Serono Japan Company Limited Clinical Trials and PubMed Articles about Serono Japan Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Serono Japan Company Limited Companies in our database. You can also find out about relevant Serono Japan Company Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...


Corporate Database Quicklinks



Searches Linking to this Company Record